Stock 4565 NXERA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:34:42 2024-04-19 am EDT 		5-day change 1st Jan Change
1,450 JPY -4.04% Intraday chart for Nxera Pharma Co., Ltd. -7.05% +2.04%
Apr. 18 Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May MT
Apr. 17 Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test MT

Business Summary

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Number of employees: 350

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
15,569 100.0 % 12,766 100.0 % -18.00%

Sales per region

JPY in Million2022Weight2023Weight Delta
Japan
48.4 %
80 0.5 % 6,173 48.4 % +7,616.25%
Switzerland
31.4 %
2,564 16.5 % 4,004 31.4 % +56.16%
United States
10.8 %
9,934 63.8 % 1,373 10.8 % -86.18%
Bermuda
9.5 %
2,849 18.3 % 1,212 9.5 % -57.46%
United Kingdom
0.0 %
142 0.9 % 4 0.0 % -97.18%

Managers

Managers TitleAgeSince
Chris Cargill CEO
 Chief Executive Officer 40 17-09-19
Shinichi Tamura FOU
 Founder 74 90-06-21
Hironoshin Nomura DFI
 Director of Finance/CFO - 22-03-23
Kazuhiko Yoshizumi CMP
 Compliance Officer 70 15-03-31
Satoshi Tanaka PRN
 Corporate Officer/Principal - 23-06-30
Kieran Johnson AUD
 Comptroller/Controller/Auditor 55 22-03-23

Members of the board

Members of the board TitleAgeSince
Shinichi Tamura FOU
 Founder 74 90-06-21
Noriaki Nagai BRD
 Director/Board Member 66 19-03-26
Rolf Soderstrom BRD
 Director/Board Member 58 20-03-24
Kuniaki Kaga BRD
 Director/Board Member 72 18-06-21
Tomohiro Toyama BRD
 Director/Board Member 74 11-05-31
David Roblin BRD
 Director/Board Member 57 18-06-21
Chris Cargill CEO
 Chief Executive Officer 40 17-09-19
Miwa Seki BRD
 Director/Board Member 59 22-03-23
Eiko Tomita BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 89,446,777 79,495,767 ( 88.87 %) 335 ( 0.000375 %) 88.87 %

Shareholders

NameEquities%Valuation
Daisuke Gomi
7.414 %
6,632,000 7.414 % 73 M ¥
Taiyo Pacific Partners LP
7.119 %
6,368,100 7.119 % 70 M ¥
JIC Venture Growth Investments Co. Ltd.
6.272 %
5,610,000 6.272 % 62 M ¥
Nomura Asset Management Co., Ltd.
3.431 %
3,068,600 3.431 % 34 M ¥
PFIZER, INC.
2.108 %
1,885,136 2.108 % 21 M ¥
Capital Research & Management Co. (World Investors)
2.058 %
1,841,200 2.058 % 20 M ¥
Asset Management One Co., Ltd.
1.920 %
1,717,600 1.920 % 19 M ¥
JPMorgan Asset Management (Japan) Ltd.
1.457 %
1,303,300 1.457 % 14 M ¥
Ichiyoshi Asset Management Co., Ltd.
1.315 %
1,175,800 1.315 % 13 M ¥
Sosei Group Restricted Stock Compensation Plan
0.7067 %
632,077 0.7067 % 7 M ¥

Holdings

NameEquities%Valuation
CENTESSA PHARMACEUTICALS PLC
1.03%
 929,353 1.03% 10,501,689 $
BIOHAVEN LTD.
0.03%
 27,308 0.03% 1,493,475 $
NXERA PHARMA CO., LTD.
0.00%
 300 0.00% 3,294 $

Company contact information

Sosei Group Corp.

PMO Hanzomon, 11/F 2-1 Koji-machi

102-0083, Tokyo

+81 3 5210 3290

https://soseiheptares.com
address Nxera Pharma Co., Ltd.(4565)

Group companies

NameCategory and Sector
Heptares Therapeutics Ltd.
Logo Heptares Therapeutics Ltd.

Heptares Therapeutics Ltd.

Pharmaceuticals: MajorHealth Technology

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Nxera Pharma Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,450 JPY
Average target price
2,100 JPY
Spread / Average Target
+44.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
NXERA PHARMA CO., LTD. Stock Nxera Pharma Co., Ltd.
+2.04% 874M
CSL LIMITED Stock CSL Limited
-5.99% 84.46B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.85B
BIOGEN INC. Stock Biogen Inc.
-24.88% 27.69B
UCB Stock UCB
+53.61% 24.28B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-8.08% 17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-33.74% 13.67B
INCYTE CORPORATION Stock Incyte Corporation
-16.63% 11.86B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.19% 11.79B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-2.25% 8.07B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4565 Stock
  4. Company Nxera Pharma Co., Ltd.